UCSF

LifeSpan Vision Ventures Invests in Deciduous Therapeutics

Retrieved on: 
Tuesday, October 3, 2023
San Francisco, University of California, San Francisco, POC, NKT, Longevity, Notifiable disease, University, Therapy, Natural killer T cell, DSM-IV codes, UCSF, Vaccine

NORWALK, Conn., Oct. 3, 2023 /PRNewswire/ -- LifeSpan Vision Ventures today announced an investment in Deciduous Therapeutics, a pioneering longevity biotechnology company dedicated to enhancing human healthspan by developing innovative medicines targeting the elimination of senescent cells through restoring endogenous immune mechanisms.

Key Points: 
  • NORWALK, Conn., Oct. 3, 2023 /PRNewswire/ -- LifeSpan Vision Ventures today announced an investment in Deciduous Therapeutics, a pioneering longevity biotechnology company dedicated to enhancing human healthspan by developing innovative medicines targeting the elimination of senescent cells through restoring endogenous immune mechanisms.
  • Originating from the research lab of Dr. Anil Bhushan at the University of California, San Francisco (UCSF), Deciduous has made groundbreaking discoveries centered on Natural Killer T-cells (NKTs) as a potent endogenous immune mechanism capable of enabling senolysis.
  • Andrew Worden, Founding Partner of LifeSpan Vision Ventures, stated: "Our investment in Deciduous Therapeutics aligns with our mission to support companies dedicated to longevity and age-related disease therapeutics.
  • Deciduous Therapeutics is taking an innovative approach to senescence, initially targeting fibrotic and metabolic diseases, but their platform technology holds immense potential for various age-related conditions.

JCR Pharmaceuticals Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)

Retrieved on: 
Friday, September 29, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Communication, Central nervous system, DSM-IV codes, Biomarker, Cerebrospinal fluid, MPS, CNS, Trial of the century, BBB, MPS I, ERT, Patient, UCSF, INN, UCSF Benioff Children's Hospital, Children's Hospital Oakland Research Institute, TSE, Hurler, Pharmaceutical industry, MD

JR-171 is a blood brain-barrier (“BBB”)-penetrating form of recombinant α-L-iduronidase that was developed using JCR’s proprietary J-Brain Cargo® technology.

Key Points: 
  • JR-171 is a blood brain-barrier (“BBB”)-penetrating form of recombinant α-L-iduronidase that was developed using JCR’s proprietary J-Brain Cargo® technology.
  • There are no approved therapies that cross the BBB and address the central nervous system (CNS) symptoms for individuals with MPS I.
  • The overall safety data concluded that JR-171 is suitable for the long-term treatment of individuals with MPS I.
  • There is no impact on the consolidated business results for this fiscal year ending on March 31, 2024, related to the matter.

Ultra Marathon Swimmer Sarah Thomas Will Attempt 50-Mile Swim in Lake Mead from Colorado River to the Hoover Dam and Make Waves to Fight Cancer with Swim Across America

Retrieved on: 
Thursday, September 28, 2023
Golden Gate Bridge, Dostarlimab, Volunteering, GSK plc, English, Sound, North Channel (Great Britain and Ireland), Health care, The New England Journal of Medicine, Johns Hopkins University, Clinical trial, Seattle Cancer Care Alliance, Cancer, SAA, Record, Hope, UCSF Benioff Children's Hospital, Research, Multimedia, Immunotherapy, Movement, Beauty, Patient, UCSF, Nantucket Cottage Hospital, Water, Atlantic Ocean, Memorial Sloan Kettering Cancer Center, Isle, Swim Across America, Hoover Dam, Weill Cornell Medicine, FDA, Children's Hospital Oakland Research Institute, Breast cancer, Hotel, Dentistry, Birth control, Dam, Pharmaceutical industry, Lake Mead, Pembrolizumab

LAS VEGAS, Sept. 28, 2023 /PRNewswire-PRWeb/ -- On October 6, 2023, ultra marathon swimmer Sarah Thomas will attempt to set another world record with a monumental swim that no other swimmer has ever attempted. Sarah will set out to complete a 50-mile swim of the entire length of Lake Mead – from the Colorado River to the Hoover Dam. She estimates the swim will take her 30 hours to complete. Sarah, a breast cancer survivor, is undertaking this swim not just to break another world record, but to help make waves in the fight against cancer and to raise critical funds for cancer research with Swim Across America.

Key Points: 
  • Sarah will set out to complete a 50-mile swim of the entire length of Lake Mead – from the Colorado River to the Hoover Dam.
  • Sarah already holds a long list of record-breaking feats and hopes to add the Lake Mead swim to her list.
  • "After my first visit to the Hoover Dam in February 2021, I knew I had to swim across Lake Mead," said Sarah.
  • Sarah's swim across Lake Mead will start in South Cove, where her favorite river, The Colorado, enters the lake.

Orange Grove Bio Subsidiary Awarded $2.05 Million SBIR Phase II Grant to Advance Development of Novel Platelet Preservation Technology

Retrieved on: 
Thursday, September 28, 2023
Heart, Maintenance, Drug development, University, Therapy, AUC, Regeneron Pharmaceuticals, PNC Center, Harvard University, SBIR, Biotechnology, University of California, San Francisco, National Heart, Lung, and Blood Institute, Pathology, OGB, Refrigeration, Head, American Academy, Research, Temperature, Lung, PNC, Autoimmunity, Bangladesh Technical Education Board, Eli Lilly, National academy, Publishing, National Academy of Medicine, Lilly, Patient, UCSF, Risk, Immune system, Small Business Innovation Research, G04, Drug discovery, Science, Transforming protein RhoA, Immunology, Health, NIH, Technology transfer, Allen Institute, Pharmaceutical industry, Vaccine, MBBS

Preservation Bio seeks to transform blood banking for donated platelets with an ex vivo additive that protects platelets from the damage normally caused by refrigeration.

Key Points: 
  • Preservation Bio seeks to transform blood banking for donated platelets with an ex vivo additive that protects platelets from the damage normally caused by refrigeration.
  • The SBIR grant will help fund Preservation Bio’s continued advancement of G04 through preclinical development and toward the clinic.
  • With more than eight million platelet units donated yearly, the global platelet market is estimated to be at least $4 billion.
  • Orange Grove Bio fosters strong relationships with technology transfer offices outside of the traditional medical technology hubs of Boston and San Francisco.

HOPPR Strengthens Executive Bench with Addition of Experts in AI, Radiology, and Health Tech Commercialization

Retrieved on: 
Tuesday, September 26, 2023
Marketing, IBM Watson, Kinect, RIS, Microsoft, Innovation, Chief technology officer, MIT, Radiology, Harvard University, Acos, Investment, UCSF, Physician, Machine learning, Algorithm, Higi, Faculty, UCLA, New York University Grossman School of Medicine, Medical device, Pharmaceutical industry, AI

Dr. Oliver Chen joins HOPPR as Chief Medical Officer, Robert Bakos as Chief Technology Officer, Ted Schwab as Chief Development Officer, and Jory Tremblay as Chief Commercial Officer.

Key Points: 
  • Dr. Oliver Chen joins HOPPR as Chief Medical Officer, Robert Bakos as Chief Technology Officer, Ted Schwab as Chief Development Officer, and Jory Tremblay as Chief Commercial Officer.
  • HOPPR co-founder Dr. Oliver Chen will serve as Chief Medical Officer.
  • Before embarking on his journey with HOPPR, Robert held the role of Chief Technology Officer at Higi, Inc., a major player in consumer health engagement.
  • Ted Schwab joins HOPPR as Chief Development Officer, bringing more than 35 years of experience in healthcare innovation and strategy, health system operations, and health tech startups.

Swim Across America Launches College Cup and College Ambassador Programs

Retrieved on: 
Tuesday, September 26, 2023
Golden Gate Bridge, Dostarlimab, Johns Hopkins University, Patient, Nantucket Cottage Hospital, Weill Cornell Medicine, Northeastern University, Environment, GSK plc, College Cup, University, Face, Seattle Cancer Care Alliance, UCSF Benioff Children's Hospital, Research, Vasa, North Star College Cup, Athlete, Swimming, UCSF, FDA, Health care, Cancer, SAA, Providence College, Immunotherapy, Outline, Water, Memorial Sloan Kettering Cancer Center, Children's Hospital Oakland Research Institute, The New England Journal of Medicine, Partnership, College, Roger Williams University, Student, Sound, Clinical trial, University of South Florida, Movement, Nursing, Hotel, Swim Across America, Pembrolizumab

CHARLOTTE, N.C., Sept. 26, 2023 /PRNewswire-PRWeb/ -- Swim Across America (SAA) is pleased to announce two new programs aimed at college students and college swim teams who want to make a bigger impact in their community through leadership, fundraising, and friendly competition. The Swim Across America College Cup features 30+ collegiate, club and alumni teams and more than 1,000 participants all united to make waves in the fight against cancer through swimming. The second program is the SAA College Ambassador program where 21 college swimmers and ambassadors have been selected to represent Swim Across America throughout the school year to help raise awareness on the importance of making waves to fight cancer. Both programs are supported through partnerships with College Swimming Coaches Association of America (CSCAA) and Vasa, the fitness training company for swimmers.

Key Points: 
  • New Programs Offer Fun, Fresh, and Exciting Ways for College Students to Make a Bigger Impact With Swim Across America, College Swimming Coaches Association of America, Inc. and Vasa are proud partners of College Cup Competition
    CHARLOTTE, N.C., Sept. 26, 2023 /PRNewswire-PRWeb/ -- Swim Across America (SAA) is pleased to announce two new programs aimed at college students and college swim teams who want to make a bigger impact in their community through leadership, fundraising, and friendly competition.
  • Through December 1, 2023, college or college-affiliated swim teams will compete in the Swim Across America College Cup , a fundraising competition among collegiate teams in the U.S.
  • Swim Across America is also excited to announce another new college initiative, the Swim Across America College Ambassadors program.
  • Earlier this year, Swim Across America invited college students to apply for the Swim Across America College Ambassadors program.

EnlitenAI Emerges as a Prominent Contender at the Digital Health Awards

Retrieved on: 
Friday, September 22, 2023
Seizure, Heart, University, Face, National Association of Epilepsy Centers, Baylor College of Medicine, Baylor University, DRS, CO, UCSF, UCHealth, Fort Collins, Colorado, Growth, Hospital, Medical device, Pharmaceutical industry, Neurology

Fort Collins,CO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- EnlitenAI , an Innosphere Ventures graduate company, proudly announces its selection as a quarterfinalist in the prestigious Digital Health Awards presented by the Digital Health Hub Foundation.

Key Points: 
  • Fort Collins,CO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- EnlitenAI , an Innosphere Ventures graduate company, proudly announces its selection as a quarterfinalist in the prestigious Digital Health Awards presented by the Digital Health Hub Foundation.
  • Out of an overwhelming 1,500 submissions, EnlitenAI has secured its spot due to its innovative focus on using AI to personalize seizure management.
  • This team has been instrumental not only in charting EnlitenAI’s functionality roadmap but also in designing groundbreaking clinical investigations."
  • Mark Goldstein, Chairman of Digital Health Hub Foundation, praised the high caliber of entrants this year, stating, "We are so impressed by the pioneering work in digital health happening on a global scale.

UCSF QBI, University College London, and Mount Sinai Identify Shared Molecular Mechanisms Across SARS-CoV-2 Variants that Allow Virus to Thrive Despite Vaccination

Retrieved on: 
Thursday, September 21, 2023
Vaccine, San Francisco, Infection, University College London, UCL, Cell Host & Microbe, Omicron, Senior, Life, HIV, Icahn School of Medicine at Mount Sinai, University, SARS-CoV-2, System, ORF6, COVID-19, Survival, University of California, San Francisco, Emerging Pathogens Institute, Viral, Research, Mount Sinai, Cell, Doctor of Philosophy, Delta, Assistant, Global Health, QBI, Genetics, Pandemic, G.H. Raisoni Department of Microbiology and Biotechnology, Quantitative Biosciences Institute, UC, UCSF, Laboratory, Pathology, SAN, CELL, School, Immune system, Gladstone Institutes, UCLA, Health, Adolfo, Virus, Pharmacy, Microbiology, Alpha

SAN FRANCISCO and LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- In a study published online in CELL today, scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings on convergent evolutionary mechanisms shared by COVID-19 variants, allowing them to overcome both adaptive and innate immune system barriers. In the paper titled, SARS-CoV-2 Variants Evolve Convergent Strategies to Remodel the Host Response, scientists carried out an unprecedented, systematic comparative study using the most infectious COVID-19 variants, namely Alpha, Beta, Gamma, Delta and Omicron to identify specific viral mutations responsible for hijacking a common host pathway, thereby leading to increased transmissibility, infectivity and survival. Specifically, they discovered a convergence in potent suppression of interferon-stimulated genes through several viral proteins, including Orf6 and Orf9b, which serve as innate immune antagonist proteins capable of blocking innate host immune response.

Key Points: 
  • The award, which included a $200,000 prize, is intended to provide support for his vision for progress against pandemic threats.
  • “Unfortunately, we continue to see new mutations and strains of SARS-CoV-2 despite innovations in new vaccines,” said Dr. Krogan, who founded the QBI Coronavirus Research Group (QCRG).
  • This finding is consistent with our investigation of early SARS-CoV-2 variants where certain viral proteins were highly expressed in infected cells which helped the virus infect our cells.
  • Their analysis pinpointed cellular pathways that are similarly modulated across variants during infection and represent putative targets for pan-coronavirus antivirals.

Medeloop Secures $8M Seed Funding to Pioneer the Future of Health Research

Retrieved on: 
Wednesday, September 20, 2023
Linda, Columbia University, Emeritus, Army, Genetics, Stanford University, LLM, EMR, PALO, Data collection, Hope, UCSD, Research, Agency for Healthcare Research and Quality, CRPS, Medicine, Doctor of Philosophy, Stanford University School of Medicine, UCSF, Investment, Patient, Bologna Business School, Diagnosis, AI, Ecosystem, McGill, Complex regional pain syndrome, Medical device, Nursing, Merck

To date, Medeloop has raised $10M in a year that will ensure continued expansion, key hires, and technological innovation.

Key Points: 
  • To date, Medeloop has raised $10M in a year that will ensure continued expansion, key hires, and technological innovation.
  • Medeloop’s AI-driven platform seamlessly integrates, harmonizes, and analyzes extensive health data using advanced AI tools that have the potential to significantly expedite the clinical research process.
  • "With an AI-driven approach, we believe Medeloop can accelerate breakthrough research to benefit patients," said Elena Viboch, Partner at General Catalyst, who will join the Medeloop board.
  • With innovative technology and a mission-focused approach, Medeloop holds the potential to transform healthcare research that can positively impact numerous patients.

Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors

Retrieved on: 
Tuesday, September 19, 2023
Oncology, Health, Infectious Diseases, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, GSK, Amgen, Ruxolitinib, University, Onyx Pharmaceuticals, Multiple myeloma, University of California, Davis, Cancer, Medicine, Antibody, Acquisition, Patient, UCSF, Hematology, Cytokine, Therapy, Margaret Klenck, Pharmaceutical industry, Indiana University, Genentech

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Barbara J. Klencke, M.D., to its board of directors.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Barbara J. Klencke, M.D., to its board of directors.
  • “Dr.
  • Dr. Klencke also serves on the Boards of Directors of eFFECTOR Therapeutics, Immune-Onc Therapeutics and TScan Therapeutics.
  • Kyprolis® is a registered trademark of Onyx Pharmaceuticals, Inc. Kadcyla®, Avastin® and Tarceva® are registered trademarks of Genentech, Inc.